Cargando…

Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma

PURPOSE: Cholecystokinin 2 (CCK-2) receptor overexpression has been demonstrated in a high percentage of medullary thyroid carcinomas (MTC). Analogous to somatostatin receptors, CCK-2 receptors might be viable targets for radionuclide scintigraphy and/or radionuclide therapy. Several CCK-2 receptor-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fröberg, Alida C., de Jong, Marion, Nock, Berthold A., Breeman, Wout A. P., Erion, Jack L., Maina, Theodosia, Verdijsseldonck, Marion, de Herder, Wouter W., van der Lugt, Aad, Kooij, Peter P. M., Krenning, Eric P.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2009
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709231/ https://www.ncbi.nlm.nih.gov/pubmed/19266197 http://dx.doi.org/10.1007/s00259-009-1098-9

Ejemplares similares

A novel CCK(2)/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study
por: Erba, Paola A., et al.
Publicado: (2018)

Targeting prostate cancer with radiolabelled bombesins
por: Maina, Theodosia, et al.
Publicado: (2006)

Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK(2)R Cancer Theranostic Agents: A Preclinical Study
por: Nock, Berthold A., et al.
Publicado: (2022)

Radiolabeled Bombesin Analogs
por: Mansi, Rosalba, et al.
Publicado: (2021)

Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Optimizing the Profile of [(99m)Tc]Tc–NT(7–13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Toward Stability Enhancement of NTS(1)R-Targeted Radioligands: Structural Interventions on [(99m)Tc]Tc-DT1
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2023)

Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11—first estimates for clinical translation
por: Kaloudi, Aikaterini, et al.
Publicado: (2016)

Comparing Gly(11)/dAla(11)-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the (111)In-SB3/(111)In-SB4 Radiotracer Pair
por: Lymperis, Emmanouil, et al.
Publicado: (2019)

[(99m)Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors
por: Roosenburg, Susan, et al.
Publicado: (2010)

One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [(99m)Tc]Tc-DB4 and [(111)In]In-SG4 in Mice Treated with Entresto
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues
por: Schroeder, Rogier P. J., et al.
Publicado: (2010)

Side-Chain Modified [(99m)Tc]Tc-DT1 Mimics: A Comparative Study in NTS(1)R-Positive Models
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2023)

[(111)In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study
por: Tatsi, Aikaterini, et al.
Publicado: (2012)

Localization of (99m)Tc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses
por: Kaloudi, Aikaterini, et al.
Publicado: (2019)

Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount
por: Konijnenberg, Mark W, et al.
Publicado: (2014)

Isotopic Scintigraphy in Intrathecal Drug Delivery Failure: A Single‐Institution Case Series
por: Delhaas, Elmar M., et al.
Publicado: (2020)

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Kwekkeboom, D. J., et al.
Publicado: (2003)

Comparative biodistribution of 12 (111)In-labelled gastrin/CCK2 receptor-targeting peptides
por: Laverman, Peter, et al.
Publicado: (2011)

[(68)Ga]Ga-DATA(5m)-LM4, a PET Radiotracer in the Diagnosis of SST(2)R-Positive Tumors: Preclinical and First Clinical Results
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2022)

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
por: Nock, Berthold A., et al.
Publicado: (2023)

[(111)In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
por: Lezaic, Luka, et al.
Publicado: (2022)

Cholecystokinin (CCK) and its receptors (CCK1R and CCK2R) in chickens: functional analysis and tissue expression
por: Wan, Yiping, et al.
Publicado: (2022)

NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [(67)Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice
por: Kaloudi, Aikaterini, et al.
Publicado: (2017)

Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours
por: Melis, Marleen, et al.
Publicado: (2009)

Radiolabeling, biodistribution and gamma scintigraphy of noscapine hydrochloride in normal and polycystic ovary induced rats
por: Priyadarshani, Anjali, et al.
Publicado: (2010)

Regulation of mammalian gastrin/CCK receptor (CCK2R) expression in vitro and in vivo
por: Ashurst, H Louise, et al.
Publicado: (2008)

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics
por: Abouzayed, Ayman, et al.
Publicado: (2023)

Gastroretentive behavior of orally administered radiolabeled tamarind seed formulations in rabbits validated by gamma scintigraphy
por: Razavi, Mahboubeh, et al.
Publicado: (2016)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients
por: Maina, Theodosia, et al.
Publicado: (2016)

A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice
por: Hornigold, David C., et al.
Publicado: (2018)

In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer
por: Bakker, Ingrid L., et al.
Publicado: (2018)

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

CCK Response Deficiency in Synphilin-1 Transgenic Mice
por: Smith, Wanli W., et al.
Publicado: (2015)

CCK2 receptors in chronic pain
por: LaVigne, Justin E., et al.
Publicado: (2022)

Imaging of inflammatory cellular protagonists in human atherosclerosis: a dual-isotope SPECT approach
por: Barrett, Hilary E., et al.
Publicado: (2020)

CCK reduces the food intake mainly through CCK1R in Siberian sturgeon (Acipenser baerii Brandt)
por: Zhang, Xin, et al.
Publicado: (2017)

The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies
por: Smith, Jill P., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rb3f535hk297ggjodukrtksd4k